Higher lorazepam doses may be riskier for seniors with weak kidneys
NCT ID NCT07179978
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at over 12,000 older adults (66+) with low kidney function who started taking lorazepam. Researchers compared higher doses (1-4 mg/day) to lower doses (0.5-1 mg/day) to see if there was a greater risk of hospitalization, emergency visits, or death within 30 days. The goal is to understand safe prescribing for this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lorazepam
What this could lead to
If it succeeds, this could help doctors prescribe safer lorazepam doses for older adults with kidney problems, reducing hospital visits and deaths.
What could go wrong
This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London Health Sciences Centre Research Institute
London, Ontario, Canada